Recent Company News

• 10:37 PM ET Aug 17, 2026
  

  Chugai Pharmaceutical, GSK sign exclusive license agreement for AID351 (¥6897.0000, +33)

• 02:41 AM ET Aug 14, 2026
  

  Chugai Pharmaceutical applies to Japan's MHLW for Tecentriq for additional indication of adjuvant treatment for MSI-High colon cancer (¥6933.0000, 0)

• 10:39 PM ET Jul 26, 2026
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 03:20 PM ET Aug 05, 2026
  

  Chugai Pharmaceutical downgraded to neutral from buy at UBS (¥6688.0000, 0)

• 02:33 AM ET Jul 31, 2026
  

  Chugai Pharmaceutical files application with Japan's MHLW for additional indication for Enspryng (¥6932.0000, 0)

• 03:11 AM ET Jul 24, 2026
  

  Chugai Pharmaceutical reports Q2 core net income ¥119.8B vs FactSet ¥130.90B [3 est, ¥117.43-139.98B] (¥7416.0000, 0)

• 07:08 PM ET Jul 21, 2026
  

  President Trump states tariff on generic drugs will stay at 0% for 2 years then rise to 100% - Truth Social

• 09:08 AM ET Jul 13, 2026
  

  BioMarin announces FDA accepts sNDA for full approval of VOXZOGO (vosoritide) for children with achondroplasia ($59.12, 0.00)

• 01:01 AM ET Jul 02, 2026
  

  Roche's divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer (CHF 328.80, 0.00)